Presentation is loading. Please wait.

Presentation is loading. Please wait.

UNEP Advisory Group Meeting Geneva, Switzerland December 12, 2014

Published byMeadow Rounsavall Modified over 9 years ago

Similar presentations

Presentation on theme: "UNEP Advisory Group Meeting Geneva, Switzerland December 12, 2014"— Presentation transcript:

1 UNEP Advisory Group Meeting Geneva, Switzerland December 12, 2014
U.S. Environmental Protection Agency Endocrine Disruptor Screening Program David Dix, Ph.D. Director, Office of Science Coordination and Policy Office of Chemical Safety and Pollution Prevention United States Environmental Protection Agency UNEP Advisory Group Meeting Geneva, Switzerland December 12, 2014 Slide 1 of 24

2 Endocrine Disruptor Screening Program (EDSP)
Established in 1998 Protection of human health and wildlife Includes estrogen, androgen and thyroid pathways Approach Prioritization based on exposure and high throughput bioactivity “Data resulting from HTPS [HTS] will be combined with exposure-related information, and with any other effects-related information that is available, for each chemical for the purpose of setting priorities for T1S [screening]” (EDSTAC 1998) Screening for bioactivity Testing for dose-response and adverse effects Prioritization Bioactivity/ Exposure Screening Bioactivity Testing Dose-Response/ Adversity More chemicals Fewer chemicals UNEP Advisory Group Meeting December 12, 2014 Slide 2 of 24

3 Current Status of EPA Prioritization & Screening
52 List 1 chemicals with complete Tier 1 datasets undergoing weight-of-evidence determination of endocrine bioactivity, possible Tier 2 testing 107 List 2 chemicals being prioritized for EDSP screening using high throughput and computational methods EDSP universe of chemicals being prioritized for EDSP screening using high throughput and computational methods FIFRA Scientific Advisory Panel peer reviews Prioritizing the Universe of Endocrine Disruptor Screening Program (EDSP) Chemicals Using Computational Toxicology Tools (January 2013) (Search under EPA docket number: EPA-HQ-OPP ) Endocrine Disruptor Screening Program (EDSP) Tier 1 Screening Assays and Battery Performance (May 2013) (Search under EPA docket number:EPA-HQ-OPP ) Endocrine Disruptor Screening Program (EDSP) Tier 2 Ecotoxicity Tests (June 2013) (Search under EPA docket number:EPA-HQ-OPP ) Weight-of-Evidence: Evaluating Results of EDSP Tier 1 Screening (July 2013) (Search under EPA docket number: EPA-HQ-OPP ) New High Throughput Methods To Estimate Chemical Exposure (July 2014) (Search under EPA docket number: EPA-HQ-OPP ) Endocrine Activity and Exposure-based Prioritization and Screening (December 2014) (Search under EPA docket ID: EPA-HQ-OPP ) UNEP Advisory Group Meeting December 12, 2014 Slide 3 of 24

4 Evolution of the EDSP Based on current pace it could take decades to screen all 10,000 chemicals for potential to interact with the endocrine system To address thousands of chemicals for potential to interact with the endocrine system, we must implement a more strategic approach to prioritize chemicals for targeted screening Recent advances in computational toxicology herald an important “evolutionary turning point” and an accelerated pace of screening and testing UNEP Advisory Group Meeting December 12, 2014 Slide 4 of 24

5 EDSP Prioritization, Screening & Testing
Bioactivity/Exposure Screening Bioactivity Testing Dose-Response/Adversity Relies on: QSARs ToxCast/ExpoCast Monitoring data OSRI ToxCast EDSP Tier 1 data EDSP Tier 2 data UNEP Advisory Group Meeting December 12, 2014 Slide 5 of 24

6 Objectives: ER Pathway
Before using the model of ER bioactivity in the EDSP framework, EPA is reviewing the scientific strengths and limitation for each goal outlined in the white paper Prioritize chemicals for further EDSP screening and testing based on estimated bioactivity Contribute to the weight of evidence evaluation of a chemical’s potential bioactivity Substitute for specific endpoints in the EDSP Tier 1 battery UNEP Advisory Group Meeting December 12, 2014 Slide 6 of 24

7 Proposed Methodological Approach
Use computational tools to model ER bioactivity – focus on agonism 16 ToxCast assays relevant to agonist pathway Model AUC for R1 (agonist) and R2 (antagonist) activities Prioritize chemicals in EDSP universe for ER agonist bioactivity UNEP Advisory Group Meeting December 12, 2014 Slide 7 of 24

8 Scientific Confidence Needed To Use [Any] New Assay
Are reference chemicals that include a range of structures and potencies accurately detected? in vitro reference chemicals In vivo reference chemicals How well do new methods compare with current methods? ToxCast versus Tier 1 results UNEP Advisory Group Meeting December 12, 2014 Slide 8 of 24

9 Scientific Confidence: ER Reference Chemicals
Excellent performance of ER AUC scores against in vitro reference chemicals Excellent performance of ER AUC scores against in vivo reference chemicals # True Pos 28 # True Neg 12 # False Pos # False Neg 4 PPV 1.0 NPV 0.75 BA 0.94 Sensitivity 0.88 Specificity Table 2.9 # True Pos 28 # True Neg 12 # False Pos 1 # False Neg PPV 0.97 NPV 0.92 BA 0.95 Sensitivity Specificity UNEP Advisory Group Meeting December 12, 2014 Slide 9 of 24

10 ER Agonist Bioactivity
UNEP Advisory Group Meeting December 12, 2014 Slide 10 of 24

11 Objectives: AR Pathway
Before using the model of AR bioactivity in EDSP framework, EPA is reviewing the scientific strengths and limitation for each goal outlined in the white paper Prioritize chemicals for further EDSP screening and testing based on estimated bioactivity UNEP Advisory Group Meeting December 12, 2014 Slide 11 of 24

12 Proposed Methodological Approach
Use computational tools to model AR bioactivity – focus on antagonism 6 ToxCast assays relevant to antagonist pathway Model AUC for R1 (agonist) and R2 (antagonist) activities Prioritize chemicals in EDSP universe for AR antagonist bioactivity UNEP Advisory Group Meeting December 12, 2014 Slide 12 of 24

13 Scientific Confidence Needed To Use [Any] New Assay
Are reference chemicals that include a range of structures and potency, accurately detected? In vitro reference chemicals In vivo reference chemicals How well do new methods compare with current methods? ToxCast versus Tier 1 results UNEP Advisory Group Meeting December 12, 2014 Slide 13 of 24

14 Scientific Confidence: Reference Chemicals
Excellent performance of ToxCast AR AUC scores against in vitro reference chemicals Performance of ToxCast AR AUC scores against in vivo reference chemicals - TBD # True Pos 14 # True Neg 8 # False Pos # False Neg 1 PPV 1.0 NPV 0.89 BA 0.97 Sensitivity 0.93 Specificity UNEP Advisory Group Meeting December 12, 2014 Slide 14 of 24

15 AR Antagonist Bioactivity
UNEP Advisory Group Meeting December 12, 2014 Slide 15 of 24

16 Objectives: IBER Before using the IBER approach in the EDSP framework, EPA is reviewing the scientific strengths and limitations of the approach Prioritize chemicals for further EDSP screening and testing based on rank of ER bioactivity and estimated exposure Prioritize chemicals for further EDSP screening and testing based on rank of AR bioactivity and estimated exposure UNEP Advisory Group Meeting December 12, 2014 Slide 16 of 24

17 Integrated Bioactivity
Proposed Method Bioactivity ToxCast Exposure ExpoCast HTTK Integrated Bioactivity Exposure Ranking (IBER) Prioritization Screening Some or All EDSP Tier 1 Assays Testing EDSP Tier 2 Assays UNEP Advisory Group Meeting December 12, 2014 Slide 17 of 24

18 Exposure Predictions for 7968 Chemicals
NHANES LoD Chemicals currently monitored by NHANES are distributed throughput the predictions Chemicals with the first and ninth highest 95% limit are monitored by NHANES UNEP Advisory Group Meeting December 12, 2014 Slide 18 of 24

19 Oral Equivalent Dose or Exposure
Combine Hazard, HTTK Dose, Exposure Output: “Activity Exposure Ratio (AER)” All ToxCast Bioactivity Dose Estimates (mg/kg/day) Oral Equivalent Dose or Exposure Exposure Estimates (mg/kg/day) Activity-Exposure Ratio Chemicals UNEP Advisory Group Meeting December 12, 2014 Slide 19 of 24

20 IBER for ER UNEP Advisory Group Meeting December 12, 2014 Slide 20 of 24

21 IBER for AR UNEP Advisory Group Meeting December 12, 2014 Slide 21 of 24

22 Integrated Bioactivity Exposure Ranking
Slide 22 of 24

23 Advantages of IBER Models will continue to be revised and improved as more data are available Provides predictions for thousands of chemicals Allows resources to be focused on chemicals more likely to have endocrine effects List 1 chemicals have limited estrogen and/or androgen receptor-mediated bioactivity Prioritizes chemicals based on bioactivity and exposure UNEP Advisory Group Meeting December 12, 2014 Slide 23 of 24

24 Current Status of EPA Prioritization & Screening
52 List 1 chemicals with complete Tier 1 datasets undergoing weight-of-evidence determination of endocrine bioactivity, possible Tier 2 testing 107 List 2 chemicals being prioritized for EDSP screening using high throughput and computational methods EDSP universe of chemicals being prioritized for EDSP screening using high throughput and computational methods FIFRA Scientific Advisory Panel peer reviews Prioritizing the Universe of Endocrine Disruptor Screening Program (EDSP) Chemicals Using Computational Toxicology Tools (January 2013) (Search under EPA docket number: EPA-HQ-OPP ) Endocrine Disruptor Screening Program (EDSP) Tier 1 Screening Assays and Battery Performance (May 2013) (Search under EPA docket number:EPA-HQ-OPP ) Endocrine Disruptor Screening Program (EDSP) Tier 2 Ecotoxicity Tests (June 2013) (Search under EPA docket number:EPA-HQ-OPP ) Weight-of-Evidence: Evaluating Results of EDSP Tier 1 Screening (July 2013) (Search under EPA docket number: EPA-HQ-OPP ) New High Throughput Methods To Estimate Chemical Exposure (July 2014) (Search under EPA docket number: EPA-HQ-OPP ) Endocrine Activity and Exposure-based Prioritization and Screening (December 2014) (Search under EPA docket ID: EPA-HQ-OPP ) UNEP Advisory Group Meeting December 12, 2014 Slide 24 of 24

Download ppt "UNEP Advisory Group Meeting Geneva, Switzerland December 12, 2014"

Similar presentations

1 EPAs 2008 Report on the Environment Denice M. Shaw, PhD U.S. Environmental Protection Agency Office of Research and Development National Center for Environmental.

1 EPAs 2008 Report on the Environment Denice M. Shaw, PhD U.S. Environmental Protection Agency Office of Research and Development National Center for Environmental.
Perspectives from EPA’s Endocrine Disruptor Screening Program

Perspectives from EPA’s Endocrine Disruptor Screening Program
Office of Research and Development Computational Toxicology and High-Throughput Risk Assessment Richard Judson U.S. EPA, National Center for Computational.

Office of Research and Development Computational Toxicology and High-Throughput Risk Assessment Richard Judson U.S. EPA, National Center for Computational.
Evaluating Existing in vitro Endocrine Data Jeff Pregenzer, Director of Endocrine Studies, CeeTox.

Evaluating Existing in vitro Endocrine Data Jeff Pregenzer, Director of Endocrine Studies, CeeTox.
Richard A. Becker, Ph.D., D.A.B.T American Chemistry Council Arlington, Virginia Comments on “Dose Setting” EDMVS Meeting July 23-24, 2002.

Richard A. Becker, Ph.D., D.A.B.T American Chemistry Council Arlington, Virginia Comments on “Dose Setting” EDMVS Meeting July 23-24, 2002.
Caird E. Rexroad, Jr. Wilbert H. Blackburn.  ARS is a matrix organization comprised of National Program Staff who establish national research program.

Caird E. Rexroad, Jr. Wilbert H. Blackburn.  ARS is a matrix organization comprised of National Program Staff who establish national research program.
1 Post-UNEP/WHO EDC State of the Science 2012 report Personal reflections by Åke Bergman, coordinator of the above mentioned report, IPCP vice chair and.

1 Post-UNEP/WHO EDC State of the Science 2012 report Personal reflections by Åke Bergman, coordinator of the above mentioned report, IPCP vice chair and.
Session III: Assessing Cumulative Effects of Endocrine Active Substances 9:15 - 9:30 Introduction” Rick Becker (Session Chair and Panel Moderator) 9:30.

Session III: Assessing Cumulative Effects of Endocrine Active Substances 9:15 - 9:30 Introduction” Rick Becker (Session Chair and Panel Moderator) 9:30.
Priority-setting for the Endocrine Disruptor Screening Program: Pesticide Active Ingredients Penelope A. Fenner-Crisp Office of Pesticide Programs U.S.

Priority-setting for the Endocrine Disruptor Screening Program: Pesticide Active Ingredients Penelope A. Fenner-Crisp Office of Pesticide Programs U.S.
National Pesticide Program A New Toxicology Testing Paradigm: Meeting Common Needs Steven Bradbury, Director Environmental Fate and Effects Division Office.

National Pesticide Program A New Toxicology Testing Paradigm: Meeting Common Needs Steven Bradbury, Director Environmental Fate and Effects Division Office.
EPA Tier I Screening Process and

EPA Tier I Screening Process and
William H. Farland, Ph.D. Acting Deputy Assistant Administrator for Science Office of Research and Development U.S. ENVIRONMENTAL PROTECTION AGENCY Biomarkers:

William H. Farland, Ph.D. Acting Deputy Assistant Administrator for Science Office of Research and Development U.S. ENVIRONMENTAL PROTECTION AGENCY Biomarkers:
EDSP Validation Gary E.Timm Senior Technical Advisor Office of Science Coordination and Policy U.S. Environmental Protection Agency.

EDSP Validation Gary E.Timm Senior Technical Advisor Office of Science Coordination and Policy U.S. Environmental Protection Agency.
Overview of the NRC Vision for the Future of Toxicity Testing Daniel Krewski, PhD, MHA Professor and Director McLaughlin Centre for Population Heath Risk.

Overview of the NRC Vision for the Future of Toxicity Testing Daniel Krewski, PhD, MHA Professor and Director McLaughlin Centre for Population Heath Risk.
Office of Research and Development National Center for Computational Toxicology April 6, 2010 Exposure-Based Chemical Prioritization Workshop: Exploring.

Office of Research and Development National Center for Computational Toxicology April 6, 2010 Exposure-Based Chemical Prioritization Workshop: Exploring.
Evolution of ICCVAM 1978 1993 ◊National Toxicology Program Develop and validate improved test methods ◊NIH Revitalization Act: P.L. 103-43 Develop and.

Evolution of ICCVAM ◊National Toxicology Program Develop and validate improved test methods ◊NIH Revitalization Act: P.L Develop and.
WILLIAM JORDAN DEPUTY DIRECTOR, OFFICE OF PESTICIDE PROGRAMS UNITED STATES ENVIRONMENTAL PROTECTION AGENCY US EPA Regulation of Endocrine Disrupting Chemicals.

WILLIAM JORDAN DEPUTY DIRECTOR, OFFICE OF PESTICIDE PROGRAMS UNITED STATES ENVIRONMENTAL PROTECTION AGENCY US EPA Regulation of Endocrine Disrupting Chemicals.
Pilot Risk-Ranking Model to Prioritize Manufacturing Sites for GMP Inspections Advisory Committee for Pharmaceutical Science Manufacturing Subcommittee.

Pilot Risk-Ranking Model to Prioritize Manufacturing Sites for GMP Inspections Advisory Committee for Pharmaceutical Science Manufacturing Subcommittee.
June 16-19, 2015 2005 USEPA Cancer Guidelines: Mode of Carcinogenic Action 1 ICABR – Impacts of the Bioeconomy on Agricultural Sustainability, the Environment.

June 16-19, USEPA Cancer Guidelines: Mode of Carcinogenic Action 1 ICABR – Impacts of the Bioeconomy on Agricultural Sustainability, the Environment.
Criteria for Screens— Review of the EDSTAC Recommendations Presentation to the EDMVS July 23, 2002.

Criteria for Screens— Review of the EDSTAC Recommendations Presentation to the EDMVS July 23, 2002.

Similar presentations

Ads by Google